Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BBO-8520 is a first-in-class direct inhibitor of KRASG12C (ON). It is being evaluated for the treatment of KRASG12C mutant non-small cell lung cancer.
Lead Product(s): BBO-8520,Pembrolizumab
Therapeutic Area: Oncology Product Name: BBO-8520
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2024
Details:
Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 TKI in development for the treatment of achondroplasia in children.
Lead Product(s): Infigratinib
Therapeutic Area: Genetic Disease Product Name: Truseltiq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2024
Details:
The net proceeds will be used to support the clinical advancement of BBO-8520, which is being evaluated in early-stage clinical trial studies in combination with pembrolizumab for the treatment of KRASG12C mutated non-small cell lung cancer.
Lead Product(s): BBO-8520,Pembrolizumab
Therapeutic Area: Oncology Product Name: BBO-8520
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cormorant Asset Management
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 02, 2024
Details:
The net proceeds will be used in the development of AG10 (acoramidis HCl). Which is being evaluated in the Phase III clinical trial studies for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Details:
Under the agreement, BridgeBio grants Bayer exclusive license to commercialize acoramidis, an investigational, next-generation, orally-administered, highly potent small molecule stabilizer of TTR, as a treatment for patients with ATTR-CM in Europe.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: $310.0 million
Deal Type: Licensing Agreement March 04, 2024
Details:
Through the acquisition, Bayer leverages the commercialization rights of AG10 (acoramidis) rights for European markets. It is a highly potent and selective small molecule, orally administered transthyretin stabilizer for the treatment of patients suffering from ATTR CM.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 04, 2024
Details:
Under the terms of the agreements, Kyowa Kirin has an exclusive license to develop and commercialize BGJ398 (infigratinib) for the treatment of achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan.
Lead Product(s): Infigratinib
Therapeutic Area: Genetic Disease Product Name: BGJ398
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: Undisclosed Upfront Cash: $100.0 million
Deal Type: Licensing Agreement February 07, 2024
Details:
AG-10 (acoramidis) is an investigational, next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin (TTR). It is being evaluated in phase 3 clinical trials for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Invitae
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 30, 2024
Details:
The net proceeds will be used in the anticipated launch of AG10 (acoramidis HCl) as the potential backbone of therapy for transthyretin amyloid cardiomyopathy (ATTR-CM).
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blue Owl Capital
Deal Size: $500.0 million Upfront Cash: $500.0 million
Deal Type: Financing January 18, 2024